Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease have?
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease has 129 citations in the OpenAlex counts ScholarIQ stores.
When was Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease published?
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease has 2019 year in the ScholarIQ index.
What is the open-access status of Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease?
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease has green oa status in the ScholarIQ index.
What is the DOI of Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease?
The DOI for Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease is on the source record.
What is the PMID of Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease?
The PMID for Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease is on the source record.
What is the OpenAlex record for Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease?
The OpenAlex for Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease is on the source record.